Group 1 - The core theme of the "AI for Good" forum was the development direction of AI chips, with a focus on making technology accessible globally [1] - Dr. Chen Ning, CEO of Yuntian Lifei, emphasized the importance of AI inference chips in achieving widespread technological benefits and addressing global challenges [1][9] - Yuntian Lifei has developed the DeepEdge10 chip platform, which includes four chips with computing power ranging from 8T to 256T, catering to various performance needs [3][4] Group 2 - The company has launched a series of AI inference products that cover cloud, edge, and terminal applications, supporting various industries such as smart cities and intelligent computing [4][6] - Yuntian Lifei's innovative architecture, "Computing Power Building Blocks," enhances chip adaptability for different scenarios, expanding the application space for domestic chips [5] - The company has made significant contributions to AI chip applications, including deploying AI models in government services and public transportation systems [6] Group 3 - Dr. Chen Ning has been recognized for his contributions to the field, leading Yuntian Lifei to win multiple prestigious awards in AI technology [7] - The company actively participates in the formulation of industry standards, having contributed to over 60 standards in AI and chip technology [8] - Yuntian Lifei has over 1,000 authorized patents, including more than 700 invention patents, showcasing its innovation capabilities [8]

Jade's Chief Executive Officer, Tom Frohlich, and Chief Scientific Officer and Head of R&D, Andrew King, BVMS, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, starting at 3:00 p.m. ET. A live webcast will be available on the Investors & Media section of Jade's website, with an archived replay accessible for 90 days following the event. SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, In ...

Core Viewpoint - Jianghuai Automobile has launched three new electric vehicle models in Colombia, aiming to promote green transportation in the region [1][10]. Group 1: New Model Launch - The newly launched models include the E30X Highland Version, E10X urban electric vehicle, and E40X intelligent electric SUV, specifically designed for high-altitude areas and urban environments [1][3]. - The E30X features a nine-in-one super electric drive system, which integrates all high-voltage components except the battery, reducing size by 40% compared to the previous generation [4]. - The E30X achieves a maximum speed of 150 km/h, accelerates from 0 to 100 km/h in just 9.4 seconds, and has a braking distance of only 37 meters, leading its class in performance [4]. Group 2: Safety and Design Features - The E30X incorporates a CTB battery body integrated collision transmission structure, enhancing safety with a torsional stiffness of 30,000 N·m/deg, which is 1.3 times that of its competitors [4]. - The E10X is designed for young consumers, featuring a stylish design and advanced smart configurations, catering to diverse urban commuting needs [6]. - The E40X is tailored for family users, equipped with full vehicle networking capabilities, voice control, smart navigation, and remote control features, along with OTA updates [9]. Group 3: Market Strategy and Brand Development - Jianghuai Automobile has been strengthening its dealer network and after-sales service in Colombia, enhancing user loyalty and brand recognition, which supports sustained sales growth [9]. - The introduction of these three electric models is expected to provide Colombian users with diverse smart travel solutions, accelerating the transition to green transportation in the country [9]. - Jianghuai's expansion in Colombia represents a key step in its global new energy strategy and illustrates the broader trend of Chinese automotive brands advancing on the international stage [10].

2025 年 7 月 7 日 银河观点集萃 责任编辑 每日晨报 周颖 ☎：010-80927635 网:zhouying_yj@chinastock.com.cn 分析师登记编码：S0130511090001 要闻 OPEC+同意将 8 月份的石油产量提高约 55 万 桶/日 www.chinastock.com.cn 证券研究报告 请务必阅读正文最后的中国银河证券股份有限公司免责声明 ● 宏观:官方劳动数据与 ADP 就业为何背离?——美国 6 月劳动数据。偏强数 据下,美股、美元和美债收益率回升,7月降息预期消散:CME 数据显示联邦 基金利率期货交易者预期 2025年在 9 月、10月出现 2 次降息, 累计 50BP, 7 月有 94.8%的概率不降息。资产方面,标普 500、纳斯达克和道琼斯指数均 明显上涨；10年期美债收益率大幅上行 6.3BP 至 4.342%，2 年期升 9.92BP 至 3.880%;美元指数上行至 97.1185;伦敦黄金下跌至 3326.085美元/盎司。 资产方面,我们认为美股短期依靠估值修复反弹后虽然创下新高,但三季度如 果硬数据进一步恶化,持续上行的趋势形成可能要等 ...

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based ...

21世纪经济报道记者韩利明上海报道 北京大学人民医院纪立农教授向21世纪经济报道等解释，"玛仕度肽是全球首个且唯一获批超重和肥胖 适应证的GCG/GLP-1双受体激动减重药物，其创新性结构修饰，将半衰期延长为10天。同时，玛仕度 肽独特的GCG靶点，促进脂肪燃烧，带来'燃脂护肝'直接获益。" 临床研究表明，使用玛仕度肽体重降幅达21%，降低肝脏脂肪含量超80%，腰围减少达11cm，颈围减少 达3cm，兼顾改善血糖、血压、血脂、血尿酸和转氨酶水平等心血管及代谢指标，带来全面获益。 当前，随着玛仕度肽获批上市，也意味着GLP-1赛道竞争进一步加剧，未来GLP-1的竞争将"卷"向何 处？5亿肥胖人群市场：玛仕度肽的定价与产能突围 根据中国诊断标准(肥胖：BMI≥28kg/m2；超重：BMI≥24kg/m2且＜28kg/m2)，中国约有5亿成人超重或 肥胖，全球排名第一。并且，近九成肥胖患者伴有一种以上合并症，接近50%的超重成人和超过80%的 肥胖成人患者最常见合并症为代谢性脂肪性肝病。 世界肥胖联盟(WOF)估计，2020年，中国的GDP因超重和肥胖导致的直接和间接损失可达2833亿美元左 右。因此，肥胖及相关慢 ...

芯片超人现有 1600平米 芯片智能仓储基地，现货库存型号 1000+ ，品牌高达 100种 ， 5000万颗 现 货库存芯片，总重量 10吨 ，库存价值高达 1亿+ 。同时，芯片超人在深圳设有独立实验室，每颗物料 均 安排QC质检 。 求购以下料号 | 品牌 | 型号 | 数量 | | --- | --- | --- | | ST | STM32G071G8U6 | 10K | | ON | NCP1096PAG | 9K | | 富士通 | MB85RC64TAPN-G AMEWE1 | 15K | | TDK | ICM-42688-P | 28K | | SENSIRION/盛思锐 | SHT15 | 2500个 | 优势物料，特价出售 累计服务1.92万用户 | 品牌 | 型号 | 数量 | 年份 | | --- | --- | --- | --- | | Vishay | NTCLE100E3102TB0 | 282000PCS | 24+ | 点击查看往期内容 ↓ ↓ ↓ 你 "在看" 我吗？ ▶ TOP4 芯片分销商，又变了 ▶ 暂停接单、原产地判定...芯片人快被逼疯了！ ▶ 4天狂卖350 ...

Core Viewpoints - The company showcased multiple early clinical products at the 2025 ADA conference, demonstrating excellent early data, particularly for LAE102, which showed good safety and pharmacokinetic properties [1][2] - The clinical and preclinical studies of LAE102, LAE103, and LAE123 indicate promising fat reduction and muscle gain effects, with LAE102 outperforming LAE103 [1][3] Events - On June 23, 2025, the company announced the clinical and preclinical research results of LAE102, LAE103, and LAE123 at the 2025 ADA conference [1] Safety and Efficacy - LAE102 demonstrated good safety with no serious adverse events (SAE) reported in both intravenous and subcutaneous administration groups, and no cases of diarrhea were noted [2] - Initial efficacy signals were observed for LAE102, with a significant increase in Actvin A levels correlating with drug dosage, indicating promising pharmacokinetic and pharmacodynamic effects [2] Clinical Pipeline - The company has a balanced pipeline focused on cancer and metabolic diseases, with several candidates in various stages of development, including LAE103 and LAE123, both in the IND application stage [3] - LAE001 and LAE005 are also in clinical trials, with LAE001 having completed Phase I trials and LAE005 showing potential in treating triple-negative breast cancer [3] Financial Projections - The company has a globalized and integrated approach to its cancer and metabolic drug development, with expectations for LAE102 to meet market demand upon commercialization [4] - Revenue projections for 2025, 2026, and 2027 are estimated at 0, 0, and 169 million respectively, with a target valuation of 16.85 billion HKD and a revised target price of 41.30 HKD [4]

China (PRC) | Healthcare Equity Research China Force in ADA 2025 All eyes on ADA'25 with key presentations during this weekend, e.g.LLY's Orfo and Bima. China biotechs will also have a presence with notable data to watch: 1) Ascletis's ASC30 (orfo-structure oral GLP-1) in Ph1, 2) Laekna's LAE102 (muscle preserving) in Ph1 and 3) Innovent's Mazdutide (GLP-1/ GCG) Ph3 data in T2D. We don't anticipate major surprises from China in ADA'25 though given oral GLP-1 and amylin candidates in early stages and no key ...

Core Viewpoint - The 28th Beijing Essen Welding and Cutting Exhibition showcased advancements in collaborative welding robots, emphasizing the theme "Intelligent Leadership for a Collaborative Future" and highlighting the potential of Huayan Robotics in the automation and intelligent welding sector [1][18]. Group 1: Product Features and Innovations - Huayan Robotics, a top three manufacturer of collaborative welding robots in China, focused on enhancing precision, adaptability, and collaboration capabilities of their robots at the Essen Exhibition [2]. - The E10L-Pro demonstrated integrated end-effector force control, requiring less than 3N of drag force for operation, significantly improving programming efficiency and simplifying welding processes [2]. - The Elfin-Pro, equipped with advanced laser sensors, can accurately identify weld seam positions and adjust the welding path in real-time, enhancing automation and reducing the need for precise manual input from welders [2]. Group 2: Expanded Capabilities - The E03-Pro, in conjunction with a seventh axis, expands the operational range to cover several meters while ensuring safety in human-robot collaboration, catering to large workpieces like ships and engineering machinery [4]. - A collaborative large-arm welding robot, designed for heavy structures, features an 1.8-meter reach, allowing it to access distant welding points without repositioning, thus improving efficiency for large-scale projects [6]. - The portable E05-Pro welding workstation is designed for mobile welding applications, allowing for easy transport and setup in confined spaces, with a high protection rating of IP66 for operation in challenging environments [8]. Group 3: Advanced Technologies - The introduction of a 3D vision system in collaborative robots enables them to autonomously identify weld seams and adjust for any positional deviations, simplifying the welding process for operators [10]. - Laser welding robots, which offer significant advantages in thin plate welding, can achieve speeds of 6-12m/min, improving efficiency by 2-3 times compared to traditional methods, while also ensuring safety through non-contact processing [12]. - The "Robot+" strategy aims to explore new application scenarios for collaborative robots, including an electric-driven mobile workstation that can autonomously navigate and adjust its height for welding tasks [14]. Group 4: Future Directions - At the 2025 Essen Welding Exhibition, Huayan Robotics plans to showcase new functionalities, products, and applications, reinforcing its commitment to innovation in collaborative robot technology and building a collaborative industrial ecosystem with global partners [18].